In this study, β-elemene was tested in patients with advanced non-small-cell lung cancer (NSCLC), advanced lung cancer, lung cancer with brain metastases, lung cancer in the older patient with EGFR mutant, advanced gastric cancer, esophageal cancer, liver cancer, colon cancer, breast cancer, cervical cancer, nasopharyngeal cancer, leukemia, lymphoma, brain tumor, ovarian cancer and endometrial cancer. This evidence concerns the gene EGFR and lung carcinoma.